Soliris (eculizumab) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 85 Diseases   26 Trials   26 Trials   4615 News 


«12...1718192021222324252627...5758»
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Severe Discoid Lupus Erythematosus Associated with Eculizumab: A Case Report and Review (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_3557;    
    It is suspected that abnormal expression of inflammatory cells and autoantibodies to multiple autoantigens are necessary for its development., This leads to the deposition of immune complexes in the tissues with stimulatory effects on B cells.4-6 There exists preliminary evidence documenting autoimmune reactions with the use of IgG2/IgG4 monoclonal antibody.7 Rarely autoimmune reactions can be seen with use of eculizumab. Reactivation of DLE could be a possible side effect.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Neuropsychiatric Manifestations of Shiga Toxin Producing E Coli Induced Hemolytic Uremic Syndrome in an Adult: A Case Report (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_2608;    
    The EAP offers an important treatment option for those patients lacking an effective management strategy for their gMG, not enrolled in an ongoing clinical trial. We present the clinical course of an adult patient with typical HUS who presented with progressively worsening neurological symptoms despite early treatment with Eculizumab and plasmapheresis, which recovered with supportive care.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Cost-Effectiveness of Eculizumab and Efgartigimod for the Treatment of generalized Myasthenia Gravis ([VIRTUAL]) -  Mar 6, 2022 - Abstract #AAN2022AAN_1753;    
    For the first time in a real-world setting, eculizumab was effective in preventing relapses and well tolerated in Japanese patients with AQP4+ NMOSD, consistent with its efficacy and safety profile in the global phase 3 PREVENT study. Eculizumab and efgartigimod, using the annual placeholder price, exceed typical willingness-to-pay thresholds which may result in limited patient access.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
    Clinical, Journal:  Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. (Pubmed Central) -  Mar 4, 2022   
    According to recent phase II-III trials, biologics significantly reduced the risk of relapses in aquaporin-4-seropositive patients, whereas results were less striking in the small cohorts of aquaporin-4-seronegative patients. Most adverse events were mild to moderate, with systemic symptoms (headache, arthralgia) or infections (upper respiratory and urinary tracts) being most commonly reported.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. (Pubmed Central) -  Mar 3, 2022   
    Cardiovascular (CV) events are the second major cause of morbidity and mortality of alloHCT survivors, after GVHD. Long-term monitoring and management of CV risk is expected to also incorporate patient stratification with CV risk prediction models, early markers of vascular dysfunction or procoagulant activity, subclinical target organ damage, arterial stiffness, and subclinical atherosclerosis.
  • ||||||||||  Voydeya (danicopan) / AstraZeneca, Soliris (eculizumab) / AstraZeneca
    Trial completion date, Monotherapy:  Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab (clinicaltrials.gov) -  Mar 2, 2022   
    P2,  N=12, Active, not recruiting, 
    Long-term monitoring and management of CV risk is expected to also incorporate patient stratification with CV risk prediction models, early markers of vascular dysfunction or procoagulant activity, subclinical target organ damage, arterial stiffness, and subclinical atherosclerosis. Trial completion date: Feb 2022 --> Jul 2022
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. (Pubmed Central) -  Feb 24, 2022   
    This landmark decision broadens the spectrum of available complement therapeutics, offering patients with unmet clinical needs or insufficient responses to anti-C5 therapy an alternative treatment option with a broad activity profile. Here we present a brief historical account of this newly approved complement drug, consolidating its approval within the long research record of the compstatin family of peptidic C3 inhibitors.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Soliris (eculizumab) / AstraZeneca
    Journal:  Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection. (Pubmed Central) -  Feb 19, 2022   
    In case of nonresponse or recurrence, additional immunosuppressive medications, such as rituximab, bortezomib, thymoglobulin, or eculizumab, were administered...Recipients with DSA-positive ABMR exhibited significantly better allograft survival after long-term application of IVIG for more than 1 year than did recipients with DSA-negative ABMR (p = 0.02). The results of our single-center cohort study involving kidney transplant recipients with ABMR suggest that long-term application of IVIG is more favorable for DSA-positive recipients, whereas intensification of maintenance immunosuppression is more effective for recipients with DSA-negative ABMR.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Patient with Hyperacute Allograft Dysfunction After Bilateral Lung Transplantation for Genetic Severe Pulmonary Hypertension (Area B, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_4685;    
    Non-HLA antibodies described in the literature include: anti-collagen V and anti-k-alpha-1 tubulin, which cannot be tested with commercial kits. It remains unclear what caused our patients hyper acute rejection and highlights the potential need for more complete antibody testing in transplant recipients.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    A Crisis of Complement? Scleroderma Renal Crisis Treated with Complement Inhibition (Area A, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_4539;    
    Our patient was begun on Eculizumab therapy after failure to respond to plasma exchange based on this concept. With the patient’s clinical improvement on Eculizumab, this case further strengthens the purported relationship between SRC and activation of the complement cascade.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    A Rare Case of Complement Mediated Thrombotic Microangiopathy (Area A, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_4499;    
    Thus, a high degree of clinical suspicion is warranted in patients presenting with TMA. Our understanding of CM-TMA is rapidly evolving, with multiple novel therapeutic agents being studied due to the cost limitations of possible life-long therapy with eculizumab.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    A Rare Non-Pulmonary Autoimmune Intrathoracic Complication of SARS-CoV-2 Infection (Room 3016/3018 (West Building, Level 3), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_2396;    
    Initially, the patient was treated with intravenous immunoglobulin and eculizumab for presumed myasthenic crisis; however, obtundation persisted...Aggressive surgical treatment in the setting of acute SARS-CoV-2 infection is indicated for this life-threatening condition. Further investigation into the molecular mechanism of SARS-CoV-2 induction of this deadly autoimmune response is warranted.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices. (Pubmed Central) -  Feb 17, 2022   
    We show that whereas complement factor 5 (C5) cleavage inhibitor eculizumab blocks all neutrophil anti-microbial functions, newer compounds like the C5 cleavage inhibitor RA101295 and C5a receptor antagonist avacopan inhibit chemotaxis and swarming while preserving neutrophil phagocytosis. These results highlight the utility of microfluidic neutrophil assays in evaluating potential complement-targeting therapeutics.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes. (Pubmed Central) -  Feb 16, 2022   
    Several authors have suggested reclassifying HUS in two entities, regardless of they are complement-mediated or not, since the use of eculizumab, an anti-C5 antibody, dramatically lowers the proportion of patients who die or suffer from end-stage renal disease within the year following diagnosis. Safety and the ideal timing of eculizumab discontinuation is currently under investigation, and the long-term consequences of HUS should be closely monitored over time once patients exit emergency departments.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. (Pubmed Central) -  Feb 15, 2022   
    New anti-C5 agents reproduce the safety and efficacy of eculizumab, with improved patient convenience. Proximal complement inhibitors have been developed to address C3-mediated extra-vascular haemolysis and seem to improve haematological response.